secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001453687-24-000035
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics FY2023 net loss $219.7M; cash runway into 2H26
---------------------------------------------------------------------

- Pro forma cash $118.3M as of Dec 31, 2023, expected to fund operations into 2H26.
- Net loss of $219.7M ($1.66/share) vs net income of $35.4M ($0.24/share) in FY2022.
- R&D expenses $71.8M, G&A $40.6M; G&A rose $16.7M on merger costs.
- Topline Phase 2b data for Descartes-08 in MG expected mid-2024; Phase 2 SLE study to start 1H24.
- Special stockholder meeting March 27, 2024 to vote on preferred conversion and 1:20-1:30 reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/0001453687-24-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368724000035/rnac-20240307.htm
  HTML page:      https://secwatch.observer/filing/0001453687-24-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer